Monoclonal Antibodies with Defined Recognition Sequences in the Stem Region of CD44

Detection of Differential Glycosylation of CD44 between Tumor and Stromal Cells in Tissue

Hirokazu Matsuki, Kayoko Yonezawa, Ken'Ichi Obata, Kazushi Iwata, Hiroyuki Nakamura, Yasunori Okada, Motoharu Seiki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CD44 is an enigmatic cell adhesion molecule acting as a major receptor for hyaluronan and playing roles in many biological and pathological processes such as lymphocyte homing, T-cell activation, wound healing, angiogenesis, and metastatic spread of tumor cells. However, the complexity of the molecule, with its alternatively spliced variants, extensive glycosylation, and processing by different proteases, has hampered detailed analysis. In this study, we prepared four monoclonal antibodies (285-2F12, 284-43F1, 268-1F5, and 294-6F2) and one polyclonal antibody (C6) that recognize defined sequences in the stem region of CD44H. Interestingly, two of the monoclonal antibodies, 268-1F5 and 294-6F2, failed to recognize the CD44 expressed in five of the seven human tumor cell lines examined by Western blotting. Treatment of the samples with a combination of neuraminidase and O-glycosidase as well as the expression of mutants with site-directed mutations at possible modification sites rendered the CD44 reactive to the antibodies. Thus, the reactivity of the antibodies is sensitive to O-glycosylation presumably near the recognition site. Glycosylation of CD44 that affects reactivity to the antibodies was found to be regulated differentially between tumor and stromal cells in two breast and three oral carcinoma tissues. Antibody 268-1F5 reacted to the tumor cells, but not to the cells in the surrounding stroma. On the other hand, the reactivity of 294-6F2 to the cells was opposite between the two tumor types. Thus, these sets of antibodies are useful to detect and analyze the as-yet-unknown roles of site-specific glycosylation of CD44, particularly in tumors.

Original languageEnglish
Pages (from-to)8278-8283
Number of pages6
JournalCancer Research
Volume63
Issue number23
Publication statusPublished - 2003 Dec 1

Fingerprint

Stromal Cells
Glycosylation
Monoclonal Antibodies
Antibodies
Neoplasms
CD44 Antigens
Biological Phenomena
Glycoside Hydrolases
Cell Adhesion Molecules
Neuraminidase
Pathologic Processes
Tumor Cell Line
Wound Healing
Breast
Peptide Hydrolases
Western Blotting
Lymphocytes
Carcinoma
T-Lymphocytes
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Monoclonal Antibodies with Defined Recognition Sequences in the Stem Region of CD44 : Detection of Differential Glycosylation of CD44 between Tumor and Stromal Cells in Tissue. / Matsuki, Hirokazu; Yonezawa, Kayoko; Obata, Ken'Ichi; Iwata, Kazushi; Nakamura, Hiroyuki; Okada, Yasunori; Seiki, Motoharu.

In: Cancer Research, Vol. 63, No. 23, 01.12.2003, p. 8278-8283.

Research output: Contribution to journalArticle

Matsuki, Hirokazu ; Yonezawa, Kayoko ; Obata, Ken'Ichi ; Iwata, Kazushi ; Nakamura, Hiroyuki ; Okada, Yasunori ; Seiki, Motoharu. / Monoclonal Antibodies with Defined Recognition Sequences in the Stem Region of CD44 : Detection of Differential Glycosylation of CD44 between Tumor and Stromal Cells in Tissue. In: Cancer Research. 2003 ; Vol. 63, No. 23. pp. 8278-8283.
@article{92f9b0eade0947faa15992ef9f8e8afb,
title = "Monoclonal Antibodies with Defined Recognition Sequences in the Stem Region of CD44: Detection of Differential Glycosylation of CD44 between Tumor and Stromal Cells in Tissue",
abstract = "CD44 is an enigmatic cell adhesion molecule acting as a major receptor for hyaluronan and playing roles in many biological and pathological processes such as lymphocyte homing, T-cell activation, wound healing, angiogenesis, and metastatic spread of tumor cells. However, the complexity of the molecule, with its alternatively spliced variants, extensive glycosylation, and processing by different proteases, has hampered detailed analysis. In this study, we prepared four monoclonal antibodies (285-2F12, 284-43F1, 268-1F5, and 294-6F2) and one polyclonal antibody (C6) that recognize defined sequences in the stem region of CD44H. Interestingly, two of the monoclonal antibodies, 268-1F5 and 294-6F2, failed to recognize the CD44 expressed in five of the seven human tumor cell lines examined by Western blotting. Treatment of the samples with a combination of neuraminidase and O-glycosidase as well as the expression of mutants with site-directed mutations at possible modification sites rendered the CD44 reactive to the antibodies. Thus, the reactivity of the antibodies is sensitive to O-glycosylation presumably near the recognition site. Glycosylation of CD44 that affects reactivity to the antibodies was found to be regulated differentially between tumor and stromal cells in two breast and three oral carcinoma tissues. Antibody 268-1F5 reacted to the tumor cells, but not to the cells in the surrounding stroma. On the other hand, the reactivity of 294-6F2 to the cells was opposite between the two tumor types. Thus, these sets of antibodies are useful to detect and analyze the as-yet-unknown roles of site-specific glycosylation of CD44, particularly in tumors.",
author = "Hirokazu Matsuki and Kayoko Yonezawa and Ken'Ichi Obata and Kazushi Iwata and Hiroyuki Nakamura and Yasunori Okada and Motoharu Seiki",
year = "2003",
month = "12",
day = "1",
language = "English",
volume = "63",
pages = "8278--8283",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Monoclonal Antibodies with Defined Recognition Sequences in the Stem Region of CD44

T2 - Detection of Differential Glycosylation of CD44 between Tumor and Stromal Cells in Tissue

AU - Matsuki, Hirokazu

AU - Yonezawa, Kayoko

AU - Obata, Ken'Ichi

AU - Iwata, Kazushi

AU - Nakamura, Hiroyuki

AU - Okada, Yasunori

AU - Seiki, Motoharu

PY - 2003/12/1

Y1 - 2003/12/1

N2 - CD44 is an enigmatic cell adhesion molecule acting as a major receptor for hyaluronan and playing roles in many biological and pathological processes such as lymphocyte homing, T-cell activation, wound healing, angiogenesis, and metastatic spread of tumor cells. However, the complexity of the molecule, with its alternatively spliced variants, extensive glycosylation, and processing by different proteases, has hampered detailed analysis. In this study, we prepared four monoclonal antibodies (285-2F12, 284-43F1, 268-1F5, and 294-6F2) and one polyclonal antibody (C6) that recognize defined sequences in the stem region of CD44H. Interestingly, two of the monoclonal antibodies, 268-1F5 and 294-6F2, failed to recognize the CD44 expressed in five of the seven human tumor cell lines examined by Western blotting. Treatment of the samples with a combination of neuraminidase and O-glycosidase as well as the expression of mutants with site-directed mutations at possible modification sites rendered the CD44 reactive to the antibodies. Thus, the reactivity of the antibodies is sensitive to O-glycosylation presumably near the recognition site. Glycosylation of CD44 that affects reactivity to the antibodies was found to be regulated differentially between tumor and stromal cells in two breast and three oral carcinoma tissues. Antibody 268-1F5 reacted to the tumor cells, but not to the cells in the surrounding stroma. On the other hand, the reactivity of 294-6F2 to the cells was opposite between the two tumor types. Thus, these sets of antibodies are useful to detect and analyze the as-yet-unknown roles of site-specific glycosylation of CD44, particularly in tumors.

AB - CD44 is an enigmatic cell adhesion molecule acting as a major receptor for hyaluronan and playing roles in many biological and pathological processes such as lymphocyte homing, T-cell activation, wound healing, angiogenesis, and metastatic spread of tumor cells. However, the complexity of the molecule, with its alternatively spliced variants, extensive glycosylation, and processing by different proteases, has hampered detailed analysis. In this study, we prepared four monoclonal antibodies (285-2F12, 284-43F1, 268-1F5, and 294-6F2) and one polyclonal antibody (C6) that recognize defined sequences in the stem region of CD44H. Interestingly, two of the monoclonal antibodies, 268-1F5 and 294-6F2, failed to recognize the CD44 expressed in five of the seven human tumor cell lines examined by Western blotting. Treatment of the samples with a combination of neuraminidase and O-glycosidase as well as the expression of mutants with site-directed mutations at possible modification sites rendered the CD44 reactive to the antibodies. Thus, the reactivity of the antibodies is sensitive to O-glycosylation presumably near the recognition site. Glycosylation of CD44 that affects reactivity to the antibodies was found to be regulated differentially between tumor and stromal cells in two breast and three oral carcinoma tissues. Antibody 268-1F5 reacted to the tumor cells, but not to the cells in the surrounding stroma. On the other hand, the reactivity of 294-6F2 to the cells was opposite between the two tumor types. Thus, these sets of antibodies are useful to detect and analyze the as-yet-unknown roles of site-specific glycosylation of CD44, particularly in tumors.

UR - http://www.scopus.com/inward/record.url?scp=0345734272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345734272&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 8278

EP - 8283

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 23

ER -